Literature DB >> 20473836

[The use of oral lacosamide in a patient with refractory partial epileptic status].

Laura Turpín-Fenoll1, Jorge Millán-Pascual, Santiago Navarro-Muñoz, Pablo del Saz-Saucedo, Ignacio Rueda-Medina.   

Abstract

INTRODUCTION: Generalised epileptic status is a medical emergency with a well-defined therapeutic algorithm. Nevertheless, in the partial status, treatment must be tailored to each patient and the risk of intensive treatment has to be assessed. Unlike generalised epileptic status, partial status is not considered a medical emergency, which means that when it comes to choosing a type of treatment the risk-benefit ratio must be carefully evaluated bearing in mind the characteristics of each particular case. CASE REPORT: A 72-year-old male with partial status secondary to an ischaemic lesion which was refractory to conventional treatment; treatment was established with lacosamide and his condition was rapidly inverted. This is the third case that has been reported of epileptic status being treated with this drug and the second in which it is employed orally.
CONCLUSIONS: Although further research is required, lacosamide could be a good therapeutic option with few interactions and side effects.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20473836

Source DB:  PubMed          Journal:  Rev Neurol        ISSN: 0210-0010            Impact factor:   0.870


  2 in total

1.  Lacosamide for epileptic seizures in patients with co-morbidities and unusual presentations of epilepsy.

Authors:  Alba Sierra-Marcos; Pedro Emilio Bermejo; Raquel Manso Calderón; Angela María Gutiérrez-Álvarez; Catalina Jiménez Corral; Daniel Sagarra Mur
Journal:  CNS Drugs       Date:  2011-12-05       Impact factor: 5.749

2.  Efficacy and tolerability of lacosamide in the concomitant treatment of 130 patients under 16 years of age with refractory epilepsy: a prospective, open-label, observational, multicenter study in Spain.

Authors:  Carlos Casas-Fernández; Antonio Martínez-Bermejo; Miguel Rufo-Campos; Patricia Smeyers-Durá; José L Herranz-Fernández; Salvador Ibáñez-Micó; Jaume Campistol-Plana; Helena Alarcón-Martínez; Jaime Campos-Castelló
Journal:  Drugs R D       Date:  2012-12-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.